Hot Features
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). ... Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.4934 | 6.09888751545 | 8.09 | 9.5699 | 8.07 | 1940296 | 8.75181385 | CS |
| 4 | 0.7084 | 8.99555555556 | 7.875 | 9.5699 | 7.47 | 2257909 | 8.45060756 | CS |
| 12 | 3.5434 | 70.3055555556 | 5.04 | 9.5699 | 4.44 | 1815469 | 7.06027654 | CS |
| 26 | 3.3734 | 64.7485604607 | 5.21 | 9.5699 | 4.44 | 1401557 | 6.46308746 | CS |
| 52 | 2.9834 | 53.275 | 5.6 | 9.5699 | 4.35 | 1105654 | 6.11231279 | CS |
| 156 | 7.0234 | 450.217948718 | 1.56 | 14.6 | 0.66 | 1370700 | 6.63510273 | CS |
| 260 | 0.5834 | 7.2925 | 8 | 14.78 | 0.66 | 864110 | 6.61947849 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.